01 / Contract Profile
75A50123C00012 Federal Contract Award
Agency code 7505
RIGEL PHARMACEUTICALS: THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO EVALUATE THE IMPACT OF FOSTAMATINIB TREATMENT DURING HOSPITALIZATION RESULTING FROM ARDS ON LONG-TERM OUTCOMES INCLUDING CLINICAL, BIOMARKER, IMAGING, QOL, FUNCTIONAL AND LUNG FUNCTI
02 / Contract Size and Status
What is the recorded size and timing of this contract?
03 / Spending Trend
75A50123C00012 contract spending by fiscal year
Annual net obligations across the complete period available for this agency and PIID, from the first recorded fiscal year through the latest contract action.
| Fiscal year | Net obligations | Actions | Change |
|---|---|---|---|
| FY 2023 | $750.0K | 3 | — |
| FY 2024 | $0 | 1 | −100.0% |
| FY 2025 | $0 | 3 | — |
04 / Federal Buyer
Which organization manages this contract?
| Department | Contracting agency | Contracting office |
|---|---|---|
| HEALTH AND HUMAN SERVICES, DEPARTMENT OF | ADMINISTRATION FOR STRATEGIC PREPAREDNESS AND RESPONSE | BARDA - ASPR / DAAPPO / BARDA DCMA |
05 / Contractor
Who holds this federal contract?
RIGEL PHARMACEUTICALS INC
UEI X7MHPBCMHFM3 · CAGE 60TS7
06 / NAICS Industries
Which industries classify this contract?
| Code | Description | Obligations | Actions | Share |
|---|---|---|---|---|
| 541715 | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) | $750.0K | 7 | 100.0% |
07 / Products and Services
What products or services were purchased?
| Code | Description | Obligations | Actions | Share |
|---|---|---|---|---|
| AN15 | HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPENSES FOR R&D FACILITIES AND MAJOR EQUIPMENT | $750.0K | 7 | 100.0% |
08 / Place of Performance
Where is the work recorded?
SOUTH SAN FRANCISCO, SAN MATEO, CALIFORNIA, UNITED STATES
ZIP 940807552
09 / Contract Actions
What modifications and obligations were recorded?
| Signed date | Modification | Obligation | Contracting office | NAICS | PSC |
|---|---|---|---|---|---|
| May 21, 2025 | P00006 | $0 | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541715 | AN15 |
| May 2, 2025 | P00005 | $0 | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541715 | AN15 |
| Mar 5, 2025 | P00004 | $0 | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541715 | AN15 |
| Jun 18, 2024 | P00003 | $0 | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541715 | AN15 |
| Dec 27, 2023 | P00002 | $0 | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541715 | AN15 |
| Aug 23, 2023 | P00001 | $0 | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541715 | AN15 |
| Apr 20, 2023 | Base action | $750.0K | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541715 | AN15 |
10 / Reading the Contract
How should this award record be interpreted?
Read the PIID as a transaction history, not as a single purchase price. Net obligations combine the base action with later increases, reductions, corrections, and deobligations recorded under the same contract.
Verify the buyer
Agency and office identify who manages the procurement relationship.
Follow modifications
Each action can change funding, scope, dates, or administrative terms.
Compare the market
Use NAICS, PSC, and the contractor profile to identify related buyers and competitors.